Fortunes Turn For Roche’s Sefaxersen As IgAN Pivot Yields Phase III Win
After faltering in eye disorders, the factor B-targeting antisense drug cut proteinuria in Phase III, setting up a challenge to Novartis’s Fabhalta.
Scrip - September 23, 2026

Novo CEO Doustdar Insists On Disciplined Dealmaking
The Danish company is looking to rebuild investor confidence and M&A is a major pillar in achieving that.
Scrip - September 23, 2026

Biopharma’s Factory Of The Future And Moving Out Of The “Dark Ages”
Leaders from Axella Biosciences, Danaher Corp, McKinsey & Co and F-Prime Capital discuss the shape of things to come in biopharma manufacturing and how industry is still in the "dark ages" when it comes to batch deviations.
Scrip - September 23, 2026

Senseonics Widens Its AID Reach With Beta Bionics As Pump Integrations Become The Growth Path
Senseonics is pairing its year-long implantable glucose sensor with Beta Bionics' iLet insulin-delivery system, targeting a Q4 2026 launch in a deal built entirely on technical compatibility.
Medtech Insight - September 23, 2026

FDA Should Improve Audits Of Stumbling Third-Party Review Program, GAO Says
FDA’s policies for auditing third-party reviewers lack specificity and are causing delays, says watchdog, as usage of the program continues to decline.
Medtech Insight - September 23, 2026

GLP-1-Driven Telemedicine Boom Could Undercut Economics Of Rx-To-OTC Switch
Telemedicine's role in widening access to prescription GLP-1 drugs may undercut the economic case for Rx-to-OTC switch, even as it creates a growing companion dietary supplement opportunity for consumer health companies.
HBW Insight - September 23, 2026

Two Lutathera Rivals Put Novartis’ Radioligand Stronghold To The Test
Lantheus and Curium have brought the first US follow-on competition to Lutathera, setting up a real-world test of whether radiopharmaceutical supply complexity can temper the erosion seen with conventional generics.
Generics Bulletin - September 23, 2026

Teva Bolsters Schizophrenia Franchise Case As Olanzapine Decision Nears
Teva has unveiled fresh Uzedy and olanzapine data as it builds a broader long-acting injectable schizophrenia franchise, while outlining the commercial infrastructure and payer hurdles shaping the products’ growth prospects.
Generics Bulletin - September 23, 2026

Kent Divestment To Phoenix Follows Private-Equity Playbook
Private-equity firm Duke Street has struck a deal to divest value-added medicines business Kent Pharmaceuticals to Irish player Phoenix Labs, expanding Phoenix’s operations in the UK.
Generics Bulletin - September 23, 2026

Edge Medical Ventures – The Transatlantic ‘C-Suite Plug-In’ for Medtech Start-Ups
Edge Medical Ventures is an Israel-US innovative medtech venture fund and incubator with an Israel venture studio and US go-to-market branch, and enjoys support from the Israel Innovation Authority. Cofounder and managing partner Gal Atarot explained Edge’s needs-driven business ethos.
In Vivo - September 22, 2026

Unnatural Products’ Long Bet On Oral Macrocycles Is Paying Off
Unnatural Products is betting that macrocyclic peptides can become a mainstream drug-discovery modality. After a decade that began in a spider-filled garage and has evolved into a string of high-profile partnerships, it may be right.
In Vivo - September 22, 2026

Strategic Intent: Rubedo’s ‘Seno-Adaptive’ Bet On Longevity Medicine
In this episode of Strategic Intent, Rubedo Life Sciences CEO Frederick Beddingfield discusses turning aging biology into drugs, Rubedo’s “seno-adaptive” approach, its AI-enabled platform and pipeline strategy.
In Vivo - September 22, 2026